Hydroxyl-substituted-2-chloro-α-(Tert-butylaminomethyl)-benzylalcohol s of the formula: ##STR1## and process for their production are disclosed. These compounds are useful as bronchodilators.

Patent
   4018818
Priority
May 16 1974
Filed
May 05 1975
Issued
Apr 19 1977
Expiry
May 05 1995
Assg.orig
Entity
unknown
2
2
EXPIRED
2. 2-Chloro-4-hydroxy-α-(tert-butylaminomethyl)-benzylalcohol and its oxalate.
1. A hydroxyl-substituted 2-chloro-α-(tert-butylaminomethyl)-benzylalcohol of the general formula ##STR4## and salts thereof.
3. A hydroxyl-substituted 2-chloro-α-(tert-butylamino-methyl)-benzylalcohol according to claim 1 which is 2-chloro-3-hydroxy-α-(tert-butylaminomethyl)-benzylalcohol and its oxalate.
4. A hydroxyl-substituted 2-chloro-α-(tert-butylamino-methyl)-benzylalcohol according to claim 1 which is 2-chloro-4-hydroxy-α-(tert-butylaminomethyl)-benzylalcohol and its oxalate.

This invention relates to hydroxyl-substituted 2-chloro-α-(tert-butylaminomethyl)-benzylalcohols of the general formula ##STR2## and a process for their production.

The compounds of this invention are useful as a medicine because of their bronchodilator activity.

According to the present invention, the above compounds are produced in two main steps:

1. a step for the preparation of hydroxyl-substituted 2-chloro-phenylglyoxal derivatives by oxidation of hydroxyl-substituted 2-chloroaceto-phenone derivatives with selenium dioxide, and

2. a step for the preparation of hydroxyl-substituted 2-chloro-α-(tert-butylaminomethyl)-benzylalcohols by reduction of the hydroxyl-substituted 2-chlorophenylglyoxal derivatives in the presence of tert-butylamine.

The process of this invention is shown according to the following chemical scheme: ##STR3##

In the first step hydroxyl-substituted 2-chloroacetophenone derivatives are oxidized in water or in an organic solvent with selenium dioxide at equimolar quantity or at an excess, to obtain hydroxyl-substituted 2-chlorophenylglyoxal derivatives. As an organic solvent, alcohols, e.g. methanol, ethanol etc. acetic acid, dioxane or their mixtures, preferably dioxane are suitable. The reaction is desirably carried out at about the boiling points of the solvents employed.

In the second step the thus obtained hydroxyl-substituted 2-chlorophenylglyoxal derivatives are reduced in the presence of tertbutylamine at an equimolar quantity or at an excess in an organic solvent such as a methanol, ethanol etc. with reducing agents such as a metal borohydride complex for example sodium- or potassium borohydride etc. to form the desired hydroxyl-substituted 2-chloro-α-(tert-butylaminomethyl)-benzylalcohols of this invention. As an organic solvent, alcohols such as methanol, ethanol etc., cyclic ethers such as tetrahydrofuran, dioxan etc., acetates such as methyl acetate, ethyl acetate, etc., or dimethylsulfoxide or dimethylformamide etc. may be mentioned.

The reaction temperature ranges from 0° C to about the boiling point of the solvent employed, preferably 0° - 10°C

As the compounds of this invention have an asymmetric carbon atom in their molecules, they are optical active and can be separated into isomers in the usual manner.

The dosage in oral administration is 1 - 5 mg, preferably 2 - 4 mg, three times a day.

The compounds of this invention can be administered not only per os., but also in the form of suppository, spray etc.

The present invention is further illustrated by the following examples.

PAC 2-Chloro-5-hydroxyphenylglyoxal

To a solution at 50° - 60° C of selenium dioxide (0.83 g) in dioxane (4.5 ml) and water (0.15 ml) was added 2-chloro-5-hydroxyacetophenone (0.85 g), and the reaction mixture was refluxed with stirring for 4 hours. The deposited selen was filtered, and the filtrate was evaporated. The residue was dissolved in ether, the ether-layer was washed with water, dried with Na2 SO4 and evaporated. The residue (0.51 g) was used to the following process.

PAC 2-Chloro-5-hydroxy-α-(tert-butylaminomethyl)-benzylalcohol

To a solution of 2-chloro-5-hydroxyphenylglyoxal (1.85 g) in methanol (37 ml) was added a solution of tert-butylamine (3.65 g) in methanol under cooling, further the sodium borohydride (0.57 g) was added in small portions, and the reaction mixture was stirred for 3 hours. The reaction mixture was evaporated and the residue acidified with 10% HCl, and washed with ether. The aqueous layer was made alkaline with K2 CO3, and extracted with ether. The extract was dried with Na2 SO4 and evaporated. The residue was recrystallized from iso-propylether n-hexane to give a 2-chloro-5-hydroxy-α-(tert-butylaminomethyl)-benzylalcohol, m.p. 162° - 163°C Hydrochloride: m.p. 245° - 248° C.

The following compounds were obtained in a similar manner.

i. 2-Chloro-3-hydroxy-α-(tert-butylaminomethyl)-benzylalcohol oxalate, m.p. 240° - 243°C

ii. 2-Chloro-4-hydroxy-α-(tert-butylaminomethyl)-benzylalcohol oxalate, m.p. 165° - 168°C

Kato, Hideo, Kurata, Sakae, Yamamoto, Yuzuro, Nishide, Kazunori

Patent Priority Assignee Title
4242359, Apr 01 1977 Cornell Research Foundation, Inc. Spermicidal agents
4419364, Sep 07 1980 AKTIEBOLAGET DRACO, A COMPANY OF SWEDEN Bronchospasmolytic carbamate derivatives
Patent Priority Assignee Title
3714229,
3732300,
/
Executed onAssignorAssigneeConveyanceFrameReelDoc
May 05 1975Hokuriku Pharmaceutical Co., Ltd.(assignment on the face of the patent)
Date Maintenance Fee Events


Date Maintenance Schedule
Apr 19 19804 years fee payment window open
Oct 19 19806 months grace period start (w surcharge)
Apr 19 1981patent expiry (for year 4)
Apr 19 19832 years to revive unintentionally abandoned end. (for year 4)
Apr 19 19848 years fee payment window open
Oct 19 19846 months grace period start (w surcharge)
Apr 19 1985patent expiry (for year 8)
Apr 19 19872 years to revive unintentionally abandoned end. (for year 8)
Apr 19 198812 years fee payment window open
Oct 19 19886 months grace period start (w surcharge)
Apr 19 1989patent expiry (for year 12)
Apr 19 19912 years to revive unintentionally abandoned end. (for year 12)